MARK C.

LAVIGNE
112 Pinckney Street, Unit #11
Boston, MA 02114
(508) 837-1427
ml6ac464@westpost.net

Education
*Ph.D., Physiology and Biophysics, Georgetown University, Washington, DC; Octobe
r, 1994-August, 1997
*M.S., Physiology and Biophysics, Georgetown University; August, 1991-October, 1
994
*B.A., Biology, St. Anselm College, Manchester, NH; September, 1983-May, 1987

Professional Experiences
Boston Scientific Corporation,
Natick, MA
December, 2006-present
Principal Scientist
*Design and execute project proposals and assays/models
*Direct project teams to determine cellular reactions to drug-eluting stent comp
onents
*Participate as a core team member in cross-functional projects with engineers a
nd polymer chemists
*Interact with a variety of company teams to create and organize new work object
ives for Cell Biology
*Manage a team of scientists to plan, design, execute, and troubleshoot cell bio
logy experiments
*Determine performance and development objectives for employees
*Write patent disclosures
*Present experimental findings as publications in scientific journals and poster
presentations at scientific meetings

Ischemix, Inc., Maynard,MA

July, 2004-August, 2006
Research Scientist
*Made the key contribution to determining mechanism of action of lead compound
*Studied ischemia-reperfusion indications, including stroke, myocardial infarcti
on, and coronary artery bypass grafting
*Directed in vitro programs to determine mechanism of action of compounds
*Managed collaborative projects with academicians in Colorado and Scotland in st
udies related to chronic obstructive pulmonary disease and compound mechanism of
action, respectively
*Prepared formal reports describing experimental rationale, design, and results

Wyeth Research,
Cambridge, MA
November, 2001-June, 2004
Post-Doctoral Fellow
*Developed in vitro models to investigate molecular mechanisms that mediate lung
abnormalities, including asthma and chronic obstructive pulmonary diseases
*Provided technical guidance for student interns and research associates
*Reported research progress in seminar format
*Published several original contributions and an invited review describing pharm
acological inhibition of adhesion molecules

Proteome, Inc.,
Beverly, MA February,
2000-November, 2001
Bioinformatacist/Curator
*Selected and integrated results of biomedical research reports pertaining to G
protein-coupled receptors

National Institute of Allergy and Infectious Diseases,

Bethesda, MD
August, 1997-January, 2001
Institutional Research Training Award (IRTA) Post-Doctoral Fellow
*Investigated structural, functional, and regulatory aspects of NADPH oxidase in
myeloid and non-myeloid mammalian cells
*Dissected mice to derive primary cultures of microglia and aortic smooth muscle
*Determined the functional role of p47phox in brain and blood vessels by retrovi
ral transduction of gene-deficient cells
*Developed transfectable cell model to study receptor-mediated activation of NAD
PH oxidase
*Received a Fellows Award for Research Excellence (2001 competition)
*Technical skills: cell culture, calcium mobilization (PTI), immunocytochemistry
, chemiluminescent detection of superoxide, genetic transfection (electroporatio
n), Western blotting, nucleotide sequencing
*Cells cultured: Primary: murine vascular smooth muscle, murine microglia; Lines
: K562, HL-60

Academic Honors and Awards

*National Institutes of Health Fellows Award for Research Excellence (2001)
*Institutional Research Training Award for post-doctoral work at the NIH (1997)
*Ph.D. Comprehensive Examination completed "With Distinction"
*Cum Laude graduate of St. Anselm College
*Washington Center Student Internship
*Endowed Scholarship from St. Anselm College

Teaching Experiences
*Invited Lecturer, Molecular Endocrinology, Georgetown University Graduate Schoo
l, Department of Physiology and Biophysics; November, 1999
*Facilitator, Medical Physiology Problem-Based Learning, Georgetown University M
edical School; 1996 and 1997
*Tutor, Physiology and Biophysics, Georgetown University Medical and Graduate Sc
hools; 1995-1997
*Substitute Teacher, Bristol-Plymouth High School; Taunton, MA; 1990

Extracurricular Activities
*Golf, Running, Tennis, Landscaping
*College Alumni Clubs, Adult Education
*Inner-City Reconstruction Programs, Road Races
*Basic Spanish

Publications
Original Contributions
1.Jabara HH, Ackerman SJ, Vercelli D, Yokota T, Arai K, Abrams J, Dvorak AM, Lav
igne MC, Banchereau J, De Vries J, Leung DYM, and Geha RS. Induction of interle
ukin-4-dependent IgE synthesis and interleukin-5-dependent eosinophil differenti
ation by supernatants of a human helper T-cell clone. Journal of Clinical Immun
ology 1988; 8:437-446.
2.Dyer KD, Lavigne MC, and Rosenberg HF. Hsp70RY: Further characterization of a
novel member of the hsp70 protein family. Biochemical and Biophysical Research
Communications 1994; 203:577-581.
3.Farhat MY, Roman CD, Shaker M, Lavigne MC, Massaro D, and Ramwell PW. Protect
ion by estradiol-17beta against the development of hypoxic pulmonary hypertensio
n in male rats. Endothelium 1995; 3:201-207.
4.Bei M, Lavigne MC, Foegh ML, Ramwell PW, and Clarke R. Specific binding of es
tradiol to rat coronary artery smooth muscle cells. Journal of Steroid Biochemi
stry and Molecular Biology 1996; 58:83-88.
5.Cathapermal S, Lavigne MC, Leong-Son MY, Alibadi T, and Ramwell PW. Stereoiso
mer-specific inhibition of superoxide anion-induced proliferation of rat aortic
smooth muscle cells by 17beta-estradiol is estrogen receptor dependent. Journal
of Cardiovascular Pharmacology 1998; 31:499-505.
6.Mills EM, Takeda K, Yu Z, Ferrans V, Katagiri Y, Jiang H, Lavigne MC, Leto TL,
and Guroff G. Nerve growth factor treatment prevents the increase in superoxid
e produced by epidermal growth factor in PC12 cells. Journal of Biological Chem
istry 1998; 273:22165-22168.
7.Thompson EW, Sung V, Lavigne M, Baumann K, Azumi N, Aaron AD, and Clarke R. L
CC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone m
etastasis. Clinical and Experimental Metastasis 1999; 17:193-204.
8.Lavigne MC, Ramwell PW, and Clarke R. Inhibition of estrogen receptor functio
n promotes porcine coronary artery smooth muscle cell proliferation. Steroids 1
999; 64:472-480.
9.Lavigne MC, Ramwell PW, and Clarke R. Growth and phenotypic characterization
of porcine coronary artery smooth muscle cells. In Vitro Cellular and Developme
ntal Biology 1999; 35:136-143.
10.Lavigne MC, Malech HL, Holland SM, and Leto TL. Genetic requirement of p47ph
ox for superoxide production by murine microglia. FASEB Journal 2001; 15:285-28
7.
11.Lavigne MC, Malech HL, Holland SM, and Leto TL. Genetic demonstration of p47
phox-dependent superoxide anion production in murine vascular smooth muscle cell
s. Circulation 2001; 104:79-84.
12.Tiffany HL, Lavigne MC, Wang JM, Gao JL, Leto TL, and Murphy PM. Amyloid-bet
a induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a
G protein-coupled receptor expressed in phagocytes and brain. Journal of Biolo
gical Chemistry 2001; 276:23645-23652.
13.Liang TS, Gao J-L, Lavigne M, Leto TL, and Murphy PM. The endogenous opioid
spinorphin blocks fMet-Leu-Phe-induced neurtrophil chemotaxis by acting as a spe
cific antagonist at the N-formylpeptide receptor subtype FPR. Journal of Immuno
logy 2001; 167:6609-6614.
14.Lavigne MC, Murphy PM, Leto TL, and Gao JL. The N-formylpeptide receptor (FP
R) and a second G (i)-coupled receptor mediate fMet-Leu-Phe-stimulated activatio
n of NADPH oxidase in murine neutrophils. Cellular Immunology 2002; 218:7-12.

15.Lavigne MC, Thakker P, Gunn J, Wong A, Miyashiro JS, Wasserman AM, Wei S-Q, P
elker J, Kobayashi M, and Eppihimer MJ. Human bronchial epithelial cells expres
s and secrete MMP-12. Biochemical and Biophysical Research Communications 2004;
324:534-546.
16.Eppihimer MJ, Sushkova N, and Lavigne MC. Differential contributions of alph
a4 and alphaL integrins to leukocyte recruitment and adhesion. Microcirculation
2004; 11:655-668.
17.Lavigne MC and Eppihimer MJ. Cigarette smoke condensate induces MMP-12 gene
expression in airway-like bronchial epithelia. Biochemical and Biophysical Rese
arch Communications 2005; 330:194-203.

Invited Reviews
1. Farhat MY, Lavigne MC, and Ramwell PW. The vascular protective effects of e
strogen. FASEB Journal 1996; 10:615-624.
2.Lavigne MC and Eppihimer MJ. Leukocyte-endothelial cell interactions: A ther
apeutic target to ameliorate inflammatory diseases. Current Medicinal Chemistry
: Anti-inflammatory and Anti-Allergy Agents 2003; 2:325-350.
3.Lavigne MC, Eppihimer MJ, Cheng R, and Barry JJ. Anti-proliferative compounds
for the prevention of restenosis, in preparation.

Book Chapter
1. Leto TL, Lavigne MC, Homoyounpour N, Lekstrom K, Linton G, Malech HL, and de
Mendez I. The K-562 cell model for analysis of neutrophil NADPH oxidase functi
on. In: Methods in Molecular Biology: Neutrophil Methods and Protocols; Quinn M
T, DeLeo FR, and Bokoch GM (eds.), 2006.